MX2021015503A - Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators. - Google Patents

Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators.

Info

Publication number
MX2021015503A
MX2021015503A MX2021015503A MX2021015503A MX2021015503A MX 2021015503 A MX2021015503 A MX 2021015503A MX 2021015503 A MX2021015503 A MX 2021015503A MX 2021015503 A MX2021015503 A MX 2021015503A MX 2021015503 A MX2021015503 A MX 2021015503A
Authority
MX
Mexico
Prior art keywords
pyridines
pyrazolo
glun2b receptor
receptor modulators
substituted heteroaromatic
Prior art date
Application number
MX2021015503A
Other languages
Spanish (es)
Inventor
Christine Gelin
Afton Hiscox
Michael A Letavic
Brice Stenne
Andrew Samant
Curt Dvorak
Christa Chrovian
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021015503A publication Critical patent/MX2021015503A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
MX2021015503A 2019-06-14 2020-06-12 Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators. MX2021015503A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861665P 2019-06-14 2019-06-14
PK34920 2020-06-03
PCT/EP2020/066384 WO2020249785A1 (en) 2019-06-14 2020-06-12 Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
MX2021015503A true MX2021015503A (en) 2022-04-20

Family

ID=73781827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015503A MX2021015503A (en) 2019-06-14 2020-06-12 Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators.

Country Status (21)

Country Link
US (2) US11530210B2 (en)
EP (1) EP3982958A1 (en)
JP (1) JP2022536424A (en)
KR (1) KR20220024512A (en)
CN (1) CN114007610A (en)
AU (1) AU2020291188A1 (en)
BR (1) BR112021025141A2 (en)
CA (1) CA3143276A1 (en)
CL (1) CL2021003257A1 (en)
CO (1) CO2021016860A2 (en)
CR (1) CR20210615A (en)
DO (1) DOP2021000250A (en)
EC (1) ECSP21090450A (en)
IL (1) IL288858A (en)
JO (1) JOP20210330A1 (en)
MA (1) MA56183A (en)
MX (1) MX2021015503A (en)
PE (1) PE20220806A1 (en)
SG (1) SG11202112405VA (en)
TW (1) TW202115054A (en)
WO (1) WO2020249785A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (en) 2016-10-06 2018-06-01 比利時商健生藥品公司 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
KR20220024511A (en) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
MX2021015500A (en) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
BR112021023562A2 (en) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their uses as glun2b receptor modulators
CA3143276A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
CN114149425A (en) * 2021-11-16 2022-03-08 上海应用技术大学 5-fluoromethylpyridine derivative and 18-F isotope labeled 5-fluoromethylpyridine derivative, and preparation and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
US6251897B1 (en) 1996-07-31 2001-06-26 Nikken Chemicals Co., Ltd 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same
JP2004501901A (en) 2000-06-26 2004-01-22 メルク　エンド　カムパニー　インコーポレーテッド Iminopyrimidine NMDANR2B receptor antagonist
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
CA2452260C (en) 2001-07-24 2011-09-06 Genset S.A. Novel variants and exons of the glyt1 transporter
WO2003082868A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EA200601266A1 (en) 2004-02-18 2007-02-27 Астразенека Аб TRIAZOLE COMPOUNDS AND THEIR APPLICATION AS ANTAGONISTS OF GLUTAMAT METABOTROPIC RECEPTOR
EP1796673A2 (en) 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2007115231A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
US9242933B2 (en) 2007-05-25 2016-01-26 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
AR068813A1 (en) 2007-08-30 2009-12-09 Takeda Pharmaceutical DERIVATIVES OF PIRAZOL REPLACED AS ANTAGONISTS OF THE ANDROGEN RECEIVER (AR), A PHARMACEUTICAL AGENT THAT UNDERSTANDS AND USES THEMSELVES IN THE TREATMENT OF PROSTATE CANCER
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
WO2009118187A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical Amide compound
NZ590688A (en) 2008-08-05 2012-09-28 Daiichi Sankyo Co Ltd imidazo[4,5-b]pyridin-2-one derivatives
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme Positive allosteric modulators of mglur2
JP5990106B2 (en) 2011-01-28 2016-09-07 佐藤製薬株式会社 Fused ring compound
JP2012188363A (en) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd Azabenzoimidazolone derivative
HUE026072T2 (en) 2011-09-19 2016-05-30 Sanofi Sa N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (en) 2012-09-11 2021-03-31 Genzyme Corp Glucosylceramide synthase inhibitors
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
AU2014233437B2 (en) 2013-03-15 2018-07-26 Opna Immuno Oncology, SA Heterocyclic compounds and uses thereof
MX365864B (en) * 2013-06-21 2019-06-18 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors.
DK3049417T3 (en) 2013-07-31 2019-01-14 Merck Patent Gmbh PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF
DK3180315T3 (en) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc pyrazoles
ES2791186T3 (en) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Triazoles as NR2B receptor inhibitors
US20170313719A1 (en) 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
MA41803A (en) 2015-03-24 2018-01-30 Almirall Sa AMINO-INDAZOLES USED AS SODIUM CHANNEL INHIBITORS
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
KR20180026760A (en) 2015-07-09 2018-03-13 얀센 파마슈티카 엔.브이. Substituted 4-azaindoles and their use as GLUN2B receptor modulators
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (en) * 2016-10-06 2018-06-01 比利時商健生藥品公司 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
BR112019026478A2 (en) 2017-06-14 2020-07-14 Trevena, Inc. compounds for modulating s1p1 activity and methods of using them
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
CN110294756A (en) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B subunit targeting type central nervous system positive electron tracer and its preparation
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
BR112021023562A2 (en) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their uses as glun2b receptor modulators
CA3143276A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015500A (en) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
KR20220024511A (en) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators

Also Published As

Publication number Publication date
WO2020249785A1 (en) 2020-12-17
US20230045960A1 (en) 2023-02-16
JP2022536424A (en) 2022-08-16
TW202115054A (en) 2021-04-16
DOP2021000250A (en) 2022-03-31
CN114007610A (en) 2022-02-01
ECSP21090450A (en) 2022-01-31
PE20220806A1 (en) 2022-05-20
JOP20210330A1 (en) 2023-01-30
BR112021025141A2 (en) 2022-01-25
MA56183A (en) 2022-04-20
SG11202112405VA (en) 2021-12-30
US20210017169A1 (en) 2021-01-21
AU2020291188A1 (en) 2022-01-20
CR20210615A (en) 2022-01-31
US11530210B2 (en) 2022-12-20
CL2021003257A1 (en) 2022-08-19
CA3143276A1 (en) 2020-12-17
CO2021016860A2 (en) 2022-01-17
EP3982958A1 (en) 2022-04-20
IL288858A (en) 2022-02-01
KR20220024512A (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2021015503A (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators.
MX2018009752A (en) Substituted 1,2,3-triazoles as nr2b-selective nmda modulators.
MX2021015500A (en) Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
MX2021005887A (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin.
JOP20210328A1 (en) Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
MX2018000352A (en) Substituted 4-azaindoles and their use as glun2b receptor modulators.
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
EA201990848A1 (en) SUBSTITUTED 1H-IMIDAZO [4,5-b] PYRIDIN-2 (3H) -ONES AND THEIR APPLICATION AS GLUN2B RECEPTOR MODULATORS
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2021015510A (en) SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS.
MX2019000588A (en) Somatostatin modulators and uses thereof.
NZ737399A (en) Ccr2 modulators
EA201591403A1 (en) SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION
WO2019193516A3 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
MX2019010949A (en) Somatostatin modulators and uses thereof.
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021015508A (en) Pyridine carbamates and their use as glun2b receptor modulators.
MX2020008106A (en) Spiro-lactam nmda receptor modulators and uses thereof.
MX2021015511A (en) Pyrazine carbamates and their use as glun2b receptor modulators.
MX2022001874A (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof.
MX2020007586A (en) Process of making somatostatin modulators.
MX2021002916A (en) Deuterium-enriched pirfenidone and methods of use thereof.
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
MX2021008941A (en) Gpr35 modulators.